Efficacy results from the Phase IV MAGNIFY-MS study and its impact on a reduction in mean combined unique active (CUA) lesion count in the first six months of cladribine (MACVENCLAD) treatment for highly active relapsing multiple sclerosis will be presented at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting. Other presentations on cladribine include:
- New data evaluating cumulative relapse incidence over five years in patients enrolled in the cladribine CLARITY and CLARITY Extension trials
- Late-breaking interim data from the CLASSIC-MS study on the long-term efficacy and real-world treatment patterns for patients receiving cladribine, with eight to 14 years of follow up, will be available as part of the late-breaker sessions from September 25, 2020
- Results from a post hoc analysis from the CLARITY Extension and the impact of cladribine on the prevalence of disability improvement over 5 years, as measured by the Expanded Disability Status Scale (EDSS)
- Results from the MAGNIFY and CLARIFY studies regarding clinical outcomes in patients with COVID-19 infection during these Phase IV studies of cladribine for the treatment of MS will be available as part of the late-breaker sessions from September 25, 2020
- Updated post-approval safety data of cladribine in the treatment of MS, including respiratory viral infections and findings that the safety profile was consistent with that from the clinical development program
For more information, visit MSVirtual 2020
